{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:26:30Z","timestamp":1748985990791},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,5]]},"DOI":"10.1097\/cm9.0000000000000341","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T13:37:59Z","timestamp":1562938679000},"page":"1765-1772","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma"],"prefix":"10.1097","volume":"132","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Yun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Rong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-Ming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bmt.1704531","article-title":"Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation","volume":"34","author":"Mohty","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1989.tb01515.x","article-title":"Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience","volume":"43","author":"Buckner","year":"1989","journal-title":"Eur J Haematol"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbmt.2016.06.026","article-title":"T cell-replete HLA haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an HLA-matched related or matched unrelated donor transplantation","volume":"22","author":"Gorgeis","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide GVHD prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41409-017-0069-1","article-title":"Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma","volume":"53","author":"Chen","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00029330-200703020-00005","article-title":"Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma","volume":"120","author":"Zhang","year":"2007","journal-title":"Chin Med J"},{"key":"R18-1-20210129","first-page":"191","article-title":"Allogeneic peripheral blood stem cell transplantation from sibling donors for 10 patients with multiple myeloma [in Chinese]","volume":"33","author":"Lan","year":"2012","journal-title":"Chin J Hematol"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bbmt.2015.04.020","article-title":"Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"21","author":"Beaussant","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kroger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2015.269","article-title":"Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma","volume":"30","author":"Ladetto","year":"2015","journal-title":"Leukemia"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.exphem.2013.08.003","article-title":"Evolving strategies with immunomodulating drugs and tandem autologous\/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.12410","article-title":"Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients","volume":"162","author":"Caballero-Vel\u00e1zquez","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00029330-201908050-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T12:22:26Z","timestamp":1612009346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201908050-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000341","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,5]]}}}